Literature DB >> 8822604

A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.

L Tengborn, B Petruson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8822604

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  20 in total

Review 1.  The use of recombinant activated coagulation factor VII for spine surgery.

Authors:  Richard B Weiskopf
Journal:  Eur Spine J       Date:  2004-05-25       Impact factor: 3.134

2.  Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.

Authors:  Shiva Keshava; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  J Thromb Haemost       Date:  2020-06-25       Impact factor: 5.824

Review 3.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 4.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

Review 5.  Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Authors:  Antonio Coppola; Annarita Tagliaferri; Gabriele Calizzani; Fabio Candura; Massimo Franchini; Carlo Ruosi; Giuliano Grazzini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

6.  Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report.

Authors:  Venancio Conesa; Andrés Navarro-Ruiz; Joaquín Borrás-Blasco; Angela Mompel; Amparo Gómez; Mercedes González
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

7.  The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.

Authors:  Giovanni Di Minno; Rainer B Zotz; Roseline d'Oiron; Niels Bindslev; Matteo Nicola Dario Di Minno; Man-Chiu Poon
Journal:  Haematologica       Date:  2015-05-22       Impact factor: 9.941

8.  Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia.

Authors:  Paola Giordano; Giuseppe Lassandro; Riccardina Tesse; Stefania Longo; Federica Valente; Anna Rita Cappiello; Antonio Coppola
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

9.  Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome.

Authors:  S Kanaji; S A Fahs; J Ware; R R Montgomery; Q Shi
Journal:  J Thromb Haemost       Date:  2014-08-26       Impact factor: 5.824

10.  Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy.

Authors:  Yoshiyuki Ogawa; Shinji Kunishima; Kunio Yanagisawa; Yohei Osaki; Yuri Uchiyama; Naomichi Matsumoto; Hideaki Tokiniwa; Jun Horiguchi; Yoshihisa Nojima; Hiroshi Handa
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.